AnaptysBio Reports Q2 2026 Results, Focuses on GSK and Vanda Collaborations

Key Facts

Reflecting a strategic shift in its business model, AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026. The company is currently prioritizing the management of financial collaborations for Jemperli with GSK and Quimilza with Vanda Pharmaceuticals. According to reports, the current strategy focuses on protecting and returning the value of its royalties to shareholders through these established partnerships.

These results arrive as key collaborations reach critical milestones, with management noting robust growth for Jemperli and anticipating FDA decisions for both Jemperli and Quimilza by year-end. Per market data, ANAB operates within a biotech sector facing specific operational hurdles, while the company works toward resolving ongoing litigation with GSK and its subsidiary Tesaro to secure its financial outlook.

ANAB shares stood at $55.20 at the close of September 18, 2026, having traded between a day low of $53.71 and a high of $55.77. Investors are looking ahead to potential catalysts, including the anticipated FDA approval of Quimilza in December 2026 and the expected judgment in the litigation with GSK, which may impact the company's fiscal trajectory.